Patient Satisfaction of BRCA1/2 Genetic Testing by Women at High Risk for Breast Cancer Participating in a Prevention Trial

By Klemp Jennifer R.   O’Dea Anne   Chamberlain Carolyn   Fabian Carol J.  

Familial Cancer, Vol. 4, Iss. 4, 2005-11 ,pp. : 279-284

Springer Publishing Company

Access to resources Recommend Favorite

Lack of Germ-line Mutations at the Specific BRCA1-IRIS Coding Sequence in 114 Spanish High-risk Breast/ovarian Families

By Hoya Miguel de la   Fernández Juan   Abajo Ana   Tosar Alicia   Díaz-Rubio Eduardo   Caldés Trinidad  

Familial Cancer, Vol. 4, Iss. 4, 2005-11 ,pp. : 317-319

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas

By Celik I.   Kars A.   Guler N.   Barista I.   Tekuzman G.   Ozyilkan O.   Hayran M.   Firat D.  

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 759-760

Elsevier

Access to resources Recommend Favorite

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin

By Berkenblit A.   Tung N.   Kim Y.   Feyler H.   Niloff J.   Berghe K.V.D.   Cannistra S.A.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 486-493

Elsevier

Access to resources Recommend Favorite

Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma

By Strauss G.   Lund B.   Hansen M.   Hansen H.H.  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 66-70

Elsevier

Access to resources Recommend Favorite